Progesterone and progesterone receptor modulators in the management of symptomatic uterine fibroids.
The majority of symptomatic uterine fibroids are currently treated by surgical interventions (myomectomy or hysterectomy) or radiological treatments (uterine artery embolisation or focussed ultrasound surgery). None of these treatments is a panacea, and what is conspicuous is the lack of an effective long-term medical therapy for a disorder so common among women of reproductive age. It has been known for some time that progesterone and its receptors enhance proliferative activity in fibroids and this has raised the possibility that anti-progestins and (PRMs) could be useful in the medical management of fibroids. Some of the compounds which have produced promising results in recent clinical trials or research studies include mifepristone, CDB-4124 (telapristone), CP-8947, J-867 (asoprisnil) and CDB-2914 (ulipristal acetate or UA). UA has recently completed Phase III clinical trials with very encouraging results, and has now acquired a licence for clinical use in Europe. While considerable research has yet to be done on the long-term safety and efficacy of UA there is nevertheless good reason for optimism on the emergence of effective medical therapy in the form of UA and possibly other PRMs.
Department of Obstetrics & Gynaecology, St. George's Hospital and University of London, Cranmer Terrace, Tooting, London SW17 0RE, United Kingdom. vtalauli@sgul.ac.uk
Vikram Sinai
VS
Talaulikar
Isaac
I
Manyonda
D004717:Endometrium / Q000187:drug effects / Q000473:pathology; D004963:Estrenes / Q000009:adverse effects / Q000627:therapeutic use; D005260:Female; D006727:Hormone Antagonists / Q000627:therapeutic use*; D006801:Humans; D006965:Hyperplasia / Q000139:chemically induced; D007436:Intrauterine Devices, Medicated; D007889:Leiomyoma / Q000188:drug therapy*; D016912:Levonorgestrel / Q000008:administration & dosage; D015735:Mifepristone / Q000009:adverse effects / Q000627:therapeutic use; D009649:Norpregnadienes / Q000009:adverse effects / Q000627:therapeutic use; D010091:Oximes / Q000009:adverse effects / Q000627:therapeutic use; D011980:Receptors, Progesterone / Q000819:agonists / Q000037:antagonists & inhibitors*
D004963:Estrenes; D006727:Hormone Antagonists; D009649:Norpregnadienes; D010091:Oximes; D011980:Receptors, Progesterone; C461063:telapristone acetate; D015735:Mifepristone; D016912:Levonorgestrel; C488516:asoprisnil; C555622:ulipristal acetate